论文部分内容阅读
目的：为了确定人血管内皮细胞生长因子（Ｖａｓｃｕｌａｒ Ｅｎｄｏｔｈｅｌｉａｌ Ｇｒｏｗｔｈ Ｆａｃｔｏｒ，ＶＥＧＦ） 在肿瘤生长及转移中的作用。方法：利用ＤＮＡ 重组技术表达人ＶＥＧＦ，以其为抗原免疫Ｂａｌｂｃ 小鼠，应用杂交瘤技术获得１４ 株稳定分泌抗ＶＥＧＦ单抗的杂交瘤细胞株。结果：ＥＬＩＳＡ 测定所分泌的单抗只与ＶＥＧＦ特异结合，与ＥＧＦ、ＦＧＦ、ＰＤＧＦ、ＴＧＦα及ＴＮＦ 等均无交叉反应。以豚鼠皮肤血管通透性实验（Ｍｉｌｅｓ） 、鸡胚绒毛尿囊膜血管形成实验（ＣＡＭ） 及人脐带静脉血管内皮细胞增殖实验（ＨｕＶＥＣ） 鉴定单抗的中和活性，其中９ 株具有中和活性。在小鼠自发乳癌肺转移模型中进行的抑瘤试验显示，单抗Ｄ１１ 对乳癌原发瘤的抑制率达８３ ．４ ％ ，对肺转移的抑制率为７１９ ％ 。结论：具有中和活性的ＶＥＧＦ单抗能抑制肿瘤的生长和转移。
Objective: To determine the role of vascular endothelial growth factor (VEGF) in tumor growth and metastasis. Methods: Human VEGF was expressed by recombinant DNA technology. Balbc mice were immunized with the antigen. Fourteen hybridoma cell lines stably secreting anti-VEGF mAb were obtained by hybridoma technique. Results: The McAbs secreted by ELISA assay only showed specific binding to VEGF and no cross-reactivity with EGF, FGF, PDGF, TGFα and TNF. The neutralizing activity of McAb was identified by guinea pig skin vascular permeability test (Miles), chick chorioallantoic membrane angioplasty (CAM) and human umbilical vein endothelial cell proliferation assay (HuVEC), of which 9 had neutralizing active. Anti-tumor experiments in a mouse model of spontaneous breast cancer lung metastasis showed that monoclonal antibody D11 had a suppression rate of 83 on primary breast cancer. 4%, the inhibition rate of lung metastasis was 719%. Conclusion: VEGF monoclonal antibody with neutralizing activity can inhibit tumor growth and metastasis.